About this trial
The purpose of this research project is to add evidence of pharmacological (0.025% atropine) and optical (Defocus Integrated Multiple Segments Triple Enhanced Design spectacle lenses ) approaches for myopia prevention among premyopic preschoolers, which may contribute to a better understanding of the intervention strategy for myopia control in premyopic children.
Eligibility criteria
This trial accepts healthy volunteersQualifiers
Age at enrollment: 5-6 years old (the senior grade of kindergarten)
Cycloplegic SE of the eye with less SE (less positive or more negative refractive error): < +1.00 D and > -0.50 D
Astigmatism: 1.5 D or less in both eyes
Anisometropia: 1.50 D or less
Disqualifiers
Strabismus or any ocular motility disorder
Any ophthalmic and systemic disorders that might affect visual functions or refractive development
Previous treatment of atropine or other myopia control intervention
Trial design
Parallel
Treatments tested in this trial
0.025% atropine eye drops
DrugDaily instillation of 0.025% atropine
DIMS TED
DeviceStepwise wearing of DIMS TED
Treatment groups
Trial outcomes
Primary outcomes
Myopic shift of spherical equivalent refraction
The change of mean cycloplegic spherical equivalent refraction over 7 years
Secondary outcomes
Axial length elongation
The change of mean axial length over 7 years
Incidence of myopia
the cumulative percentage of incident myopia
Fast myopic shift of spherical equivalent refraction
the cumulative percentage of fast myopic shift of spherical equivalent refraction
Subfoveal choroidal thickness
the vertical distance from the outer edge of the retinal pigment epithelium (or Bruch's membrane) to the inner surface of the sclera (the chorioscleral border) directly beneath the fovea
Locations
Sponsors and contacts
Click on the lead sponsor to view all of their trials.
This trial is not recruiting at the moment. You can still explore other options: